The development of resolvin-encapsulated negatively-charged liposome for the therapy of acute lung injury

2017 Fiscal Year Final Research Report

• Project/Area Number: 26861528
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Emergency medicine
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Tabata Yuichi 京都府立医科大学, 医学(系)研究科(研究院), 助教 (70515238)
• Research Collaborator: Sawa Teiji 京都府立医科大学, 医学研究科, 教授 (10206013)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 炎症消退脂質 / レゾルビン / リポソーム / 炎症 / 肺炎 / 急性呼吸窮迫症候群

Outline of Final Research Achievements

Recent findings indicate that the resolution of inflammation tends toward being an active process that enables inflamed tissues to return to a state of homeostasis. This process is facilitated by pro-resolving lipid mediators, which are mainly derived from ω6-polyunsaturated fatty acids (PUFA). The bioactive pro-resolving lipid molecules are lipotoxins, resolvins, and protectins. The resolution of inflammation requires pro-resolving mediator-activated programs that stop neutrophil infiltration to inflamed tissues, promote the uptake and clearance of apoptotic inflammatory cells, and stimulate the antimicrobial activities of mucosal epithelial cells. In this study, we developed resolvin-encapsulated negatively-charged liposomes and evaluated the anti-inflammatory effects in in-vitro and in-vivo models. The preliminary findings suggest new possibilities in the development of novel approaches and pharmaceutical therapeutics for the treatment of inflammatory diseases in critical care.

Free Research Field

集中治療医学